Information Provided By:
Fly News Breaks for February 25, 2019
BGNE
Feb 25, 2019 | 17:05 EDT
Cowen analyst Yaron Werber assumed coverage of BeiGene with an Outperform rating and $170 price target. Werber believes Zanubrutinib and tislelizumab should be approved in the first half of 2019 in China, and sees several pivotal studies in other indications driving label expansion in 2020-2022. The analyst anticipates $1.2B in global sales for Zanubrutinib.
News For BGNE From the Last 2 Days
There are no results for your query BGNE
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.